Assis, David N.

Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases

Mack, C. L., Adams, D., Assis, D. N., Kerkar, N., Manns, M. P., Mayo, M. J., Vierling, J. M., Alsawas, M., Murad, M. H., & Czaja, A. J. (2020) · Hepatology

Liver Diseases and ImmunityIgG4-Related and Inflammatory Diseases

Cited by 983

Fibrates and cholestasis

Ghonem, N. S., Assis, D. N., & Boyer, J. L. (2015) · Hepatology

Drug Transport and Resistance MechanismsLiver Diseases and Immunity

Cited by 317

Effects of vedolizumab in patients with primary sclerosing cholangitis and inflammatory bowel diseases

Lynch, K. D., Chapman, R. W., Keshav, S., Montano-Loza, A. J., Mason, A. L., Kremer, A. E., Vetter, M., de Krijger, M., Ponsioen, C. Y., Trivedi, P., et al. (2020) · Clinical Gastroenterology and Hepatology

Liver Diseases and ImmunityInflammatory Bowel Disease

Cited by 105

Defining primary sclerosing cholangitis: results from an International Primary Sclerosing Cholangitis Study Group consensus process

Ponsioen, C. Y., Assis, D. N., Boberg, K. M., Bowlus, C. L., Deneau, M., Thorburn, D., Aabakken, L., Färkkilä, M., Petersen, B., Rupp, C., et al. (2021) · Gastroenterology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 95

Clinical utility of genomic analysis in adults with idiopathic liver disease

Hakim, A., Zhang, X., DeLisle, A., Oral, E. A., Dykas, D., Drzewiecki, K., Assis, D. N., Silveira, M., Batisti, J., Jain, D., et al. (2019) · Journal of Hepatology

Genomics and Rare DiseasesLiver Disease Diagnosis and Treatment

Cited by 81

Fenofibrate Improves Liver Function and Reduces the Toxicity of the Bile Acid Pool in Patients With Primary Biliary Cholangitis and Primary Sclerosing Cholangitis Who Are Partial Responders to Ursodiol

Ghonem, N. S., Auclair, A. M., Hemme, C. L., Gallucci, G. M., de la Rosa Rodriguez, R., Boyer, J. L., & Assis, D. N. (2020) · Clinical Pharmacology & Therapeutics

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 57

Fenofibrate Downregulates NF-κB Signaling to Inhibit Pro-inflammatory Cytokine Secretion in Human THP-1 Macrophages and During Primary Biliary Cholangitis

Gallucci, G. M., Alsuwayt, B., Auclair, A. M., Boyer, J. L., Assis, D. N., & Ghonem, N. S. (2022) · Inflammation

Liver Diseases and ImmunityPeroxisome Proliferator-Activated Receptors

Cited by 46

PPAR-Mediated Bile Acid Glucuronidation: Therapeutic Targets for the Treatment of Cholestatic Liver Diseases

Gallucci, G. M., Hayes, C. M., Boyer, J. L., Barbier, O., Assis, D. N., & Ghonem, N. S. (2024) · Cells

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 40

Advancing diagnosis and management of liver disease in adults through exome sequencing

Zheng, M., Hakim, A., Konkwo, C., Deaton, A. M., Ward, L. D., Silveira, M. G., Assis, D. N., Liapakis, A., Jaffe, A., Jiang, Z. G., et al. (2023) · EBioMedicine

Genomics and Rare DiseasesMetabolism and Genetic Disorders

Cited by 34

A systematic review of patient-reported outcomes in primary biliary cholangitis and primary sclerosing cholangitis

Kim, H. P., Lieber, S. R., Rogers, M. E., Moon, A. M., Loiselle, M., Walker, J., Assis, D. N., Safer, R., Gomel, R., & Evon, D. M. (2020) · Hepatology Communications

Liver Diseases and ImmunityHealth Education and Validation

Cited by 27

Adjunct Fenofibrate Up‐regulates Bile Acid Glucuronidation and Improves Treatment Response For Patients With Cholestasis

Gallucci, G. M., Trottier, J., Hemme, C., Assis, D. N., Boyer, J. L., Barbier, O., & Ghonem, N. S. (2021) · Hepatology Communications

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 26